Get started
Author

Peter I-Fan Wu

Observed name: Peter I. Wu
ORCID: 0000-0001-5570-4871
Observed ORCID: 0000-0001-5570-4871
OpenAlex ID: A5017116530
Chemical-genetic interrogation of RNA polymerase mutants reveals structure-function relationships and physiological tradeoffs
2021 · Anthony L. Shiver, Hendrik Osadnik, et al. · Molecular Cell · 22
PDF
Phenotype annotation with the ontology of microbial phenotypes (OMP)
2019 · Deborah A. Siegele, Sandra A. LaBonte, et al. · Journal of Biomedical Semantics · 10
PDF
Phenotypic Associations Among Cell Cycle Genes in Saccharomyces cerevisiae
2020 · María Bermudez-Cruz, Peter I. Wu, et al. · G3 Genes Genomes Genetics · 2
Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al. · Clinical Cancer Research · 1
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial
2026 · Priscilla Merriam, James J. Morrow, et al. · Nature Medicine · 1
PDF
Insights from the reanalysis of high-throughput chemical genomics data for Escherichia coli K-12
2020 · Peter I-Fan Wu, Curtis Ross, et al. · G3 Genes Genomes Genetics · 1
Supplementary Table S5 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Table S1 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Table S4 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Table S2 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Table S3 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Figure S5 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Figure S6 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Figure S1 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Data from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Figure S3 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Figure S2 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Figure S4 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
2026 · Aman Chauhan, Heidi L. Weiss, et al.
Supplementary Table S3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Figure 1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Table 1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Table S4 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Supplementary Figure S3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Data from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Table 2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
2026 · Atish D. Choudhury, Caiwei Zhong, et al.
Works count: 38
Citation count: 37
H-index: 2
I10-index: 2
Year
Topic
Type